BIOGEN INC. Restructuring Costs
BIOGEN INC. (BIIB) reported Restructuring Costs of $10.30 million for the 12-month period ending 2016-12-31, per its 10-K filed 2017-02-02.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:RestructuringCosts · last filed 2017-02-02
- BIOGEN INC. restructuring costs for the quarter ending 2016-06-30 was $0.00.
- BIOGEN INC. restructuring costs for the quarter ending 2016-03-31 was $10.30M.
- BIOGEN INC. restructuring costs for fiscal 2016 was $10.30M.
| Period end | Restructuring Costs 3 month | Restructuring Costs 6 month | Restructuring Costs 12 month |
|---|---|---|---|
| 2016-12-31 | $10.30M 10-K · filed 2017-02-02 | ||
| 2016-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2016-07-21 | $10.30M 10-Q · filed 2016-07-21 | |
| 2016-03-31 | $10.30M 10-Q · filed 2016-04-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |